Full year 2023 for the period 1 January - 31 December (Q4'2023 results in brackets):
Net revenue was KDKK 0 (0)
Operating result was KDKK -22.510 (-4.852)
Net result was KDKK -26.527 (-12.009)
Cash at bank end of the period was KDKK 3.373 (3.373)
Earnings per share* was KDKK -1,92 (-0,87)
Solidity** was -23% (-23%)
*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of
**Solidity: Total equity divided by total capital and liability.
Highlights during the full year 2023.
Q1-2023
Based on ongoing stability studies of CT001, CT001 has been shown to be stable over a prolonged period of time and is now estimated to have a shelf-life of more than two years at controlled room temperature. This will greatly benefit the future supply chain management and will be a major advantage for the hospitals and clinics storing and working with CT001.
Q2-2023
The Company announced that it entered into an exclusive US license and collaboration agreement with
Ventis Pharma Corporation - a biopharmaceutical company focused on developing and formulating innovative pain management therapies - for the development and commercialization of CT001 for the US market. Under the agreement both parties,Cessatech and Ventis Pharma will share costs and net profits 50/50 with the potential to generate revenues from 2024, much earlier than originally anticipated.
Q3-2023
During Q3'2023 we successfully managed to add an extra product to the development pipeline. CT002 is developed to address the unmet medical need of a non-invasive sedative procedure for children undergoing MRI scanning or other procedures requiring sedation.
Q4-2023
The 0205 data demonstrated that CT001 had significant reduction in the pain scale, and although superiority was not achieved for the sufentanil control arm in adults the co-primary endpoint of preliminary modelled exposure-response data substantiates that CT001 is superior in children.
The annual report is presented for approval at the Annual General Meeting,
For more information about
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
About
https://news.cision.com/cessatech/r/cessatech-a-s-publishes-annual-report-for-the-fiscal-year-2023,c3938152
https://mb.cision.com/Main/19921/3938152/2637874.pdf
(c) 2024 Cision. All rights reserved., source